Hepatic Encephalopathy Management with Rifaximin Substitution

Alternative Medication Options

The American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) recommend neomycin as an alternative choice for treatment of overt hepatic encephalopathy with a Grade II-1, B, 2 recommendation 1
Metronidazole is another alternative choice for treatment of overt hepatic encephalopathy, but has significant limitations for long-term use due to risks of ototoxicity, nephrotoxicity, and neurotoxicity (Grade II-3, B, 2) 1
L-Ornithine-L-Aspartate (LOLA) can be used as an alternative agent for patients nonresponsive to conventional therapy, with a Grade I, B, 2 recommendation 3

Neomycin has been widely used in the past for HE treatment and is a known glutaminase inhibitor, effective in reducing ammonia levels, but carries risks of ototoxicity, nephrotoxicity, and neurotoxicity 1, 2
Metronidazole is effective for short-term therapy of hepatic encephalopathy, but has significant limitations for long-term use due to risks of ototoxicity, nephrotoxicity, and neurotoxicity 1, 2

The American Association for the Study of Liver Diseases (AASLD) recommends continuing lactulose at current dose and adding neomycin 1-2g orally 2-4 times daily as a first-line substitution for rifaximin 1
Regular monitoring of renal function is essential when using neomycin due to nephrotoxicity risk 1

Lactulose remains the cornerstone of therapy and should be continued even when adding an alternative to rifaximin, according to the American Association for the Study of Liver Diseases (AASLD) 4
The European Association for the Study of the Liver (EASL) recommends avoiding simple laxatives as they lack the prebiotic properties of disaccharides like lactulose 4
Probiotics may be considered as a potential adjunctive therapy, as some studies show they may have similar efficacy to lactulose in preventing HE recurrence, according to the American Association for the Study of Liver Diseases (AASLD) 1